TC Biopharm plans to begin Proof of Concept preclinical studies for TCB008

TC BioPharm (TCBP) announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB008, for treatment in H5N1, commonly known as “Bird Flu.” The Company is currently approaching potential university partners to expedite the preclinical work required for a Phase I study. H5N1 is a viral infection often contracted by contact with sick birds, yet it can also be passed from person to person. Symptoms begin within two to eight days and can seem like the common flu, causing cough, fever, sore throat, muscle aches, headache, and shortness of breath. TCB008 is an allogeneic, unmodified cell therapy made up of activated and expanded gamma delta T, or GDT, cells, which the company expects will have applications in treating the emerging avian bird flu epidemic. Due to the highly infectious nature of H5N1, TC BioPharm’s goal would be to partner with a leading Infectious Disease Center or University to advance the Proof-of-Concept and pre-clinical studies.